SCHEMBL1628660

SCHEMBL1628660

COC(=O)c1ccc(CCCCO)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 5/20 1.00
CYP4F2 P78329 4/20 1.00
POLB P06746 1/20 0.61
LOXL2 Q9Y4K0 1/20 0.58
DHODH Q02127 1/20 0.53
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
ALOX12 P18054 1/20 0.51
CYP2C19 P33261 1/20 0.51
CKS1B P61024 1/20 0.51
SKP2 Q13309 1/20 0.51
HIF1A Q16665 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPT P10636 2/20 0.50
CA1 P00915 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654656 0.98 CYP4A11 (0.97) CYP4A11CYP4F2POLBLOXL2DHODH
SCHEMBL1796445 0.98 CYP4A11 (0.97) CYP4A11CYP4F2POLBLOXL2DHODH
SCHEMBL2654036 0.98 CYP4A11 (0.97) CYP4A11CYP4F2POLBLOXL2DHODH
SCHEMBL2653147 0.98 CYP4A11 (0.97) CYP4A11CYP4F2POLBLOXL2DHODH
SCHEMBL2654777 0.95 CYP4A11 (1.00) CYP4A11CYP4F2POLBLOXL2DHODH
1,4-Butanediol SCHEMBL2722579 0.89 CYP4A11 (0.79) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL2655571 0.87 CYP4A11 (0.79) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL18106036 0.87 CYP4A11 (0.79) CYP4A11CYP4F2POLBLOXL2DHODH
SCHEMBL8044139 0.86 CYP4A11 (0.75) CYP4A11CYP4F2LOXL2ALDH1A1MAPT
SCHEMBL10641751 0.86 CYP4A11 (0.75) CYP4A11CYP4F2LOXL2DHODHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606625-A Moisture-heat-resistant polyurethane heat-conducting structural adhesive and preparation method thereof 广东德聚技术股份有限公司 2023-08-18 CN claimed
EP-4692061-A1 LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF Aevis Bio, Inc. (KR) 2026-02-11 EP disclosed
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
EP-4667467-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2025-12-24 EP disclosed
WO-2024205319-A1 LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF 주식회사 아이비스바이오 2024-10-03 WO disclosed
CN-116606625-A Moisture-heat-resistant polyurethane heat-conducting structural adhesive and preparation method thereof 广东德聚技术股份有限公司 2023-08-18 CN disclosed
US-11612662-B2 Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds NEKTAR THERAPEUTICS (US) 2023-03-28 US disclosed
US-20230091810-A1 FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2023-03-23 US disclosed
US-11565994-B2 Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) THE JOHNS HOPKINS UNIVERSITY (US) 2023-01-31 US disclosed
US-11565994-B2 Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) THE JOHNS HOPKINS UNIVERSITY (US) 2023-01-31 US disclosed
EP-0593603-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-04-27 EP disclosed
WO-1993000095-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-01-07 WO disclosed
US-4895946-A Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1990-01-23 US disclosed
EP-0162208-B1 NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) 1989-11-23 EP disclosed
US-4871743-A L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-10-03 US disclosed
EP-0325343-A2 L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-07-26 EP disclosed
EP-0314280-A2 Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-05-03 EP disclosed
US-4683234-A HYPOTENSIVE AGENTS, ANTI-ANGINA SUNTORY LIMITED (JP) 1987-07-28 US disclosed
EP-0162208-A2 Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) 1985-11-27 EP disclosed
US-4024173-A Process for the manufacture of cyclohexene dicarboxylic acid esters DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11612662-B2 Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds PAICS, MTHFD2, MTHFD1 CYP4A11 3483/4885CYP4F2 2890/4885POLB 132/4885
US-11565994-B2 Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) KDM1B, KDM2A, EHMT2 CYP4A11 3135/4885CYP4F2 1361/4885POLB 1446/4885
US-20230091810-A1 FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS MTHFD1, SHMT1, SHMT2 CYP4A11 816/4885CYP4F2 37/4885POLB 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.